The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Summary of the document prepared by the Czech Society of Cardiology

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F18%3A73592003" target="_blank" >RIV/61989592:15110/18:73592003 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023001:_____/18:00077230

Výsledek na webu

<a href="https://e-coretvasa.cz/pdfs/cor/2018/04/20.pdf" target="_blank" >https://e-coretvasa.cz/pdfs/cor/2018/04/20.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.crvasa.2018.05.001" target="_blank" >10.1016/j.crvasa.2018.05.001</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Summary of the document prepared by the Czech Society of Cardiology

Popis výsledku v původním jazyce

Introduction Non-vitamin K antagonist oral anticoagulants (NOACs) have emerged as an alternative for vitamin K antagonists (VKAs) for thrombo-embolic prevention in patients with non-valvular atrial fibrillation (AF). Some authors refer to these drugs as ‘direct oral anticoagulants’ (DOACs), but since the term NOAC has been used for many years and is widely recognized, we prefer to continue to use NOAC. Non-vitamin K antagonist oral anticoagulants have an improved efficacy/safety ratio, predictable effect without need for routine monitoring, and fewer food and drug interactions compared with VKAs. However, the proper use of NOACs requires different approaches to many practical aspects compared with VKAs. The European Heart Rhythm Association (EHRA) set out to coordinate a unified way of informing physicians on the use of NOACs. A first Practical Guide was published in 2013 to supplement the AF guidelines as a guidance for safe, effective use of NOAC when prescribed. This text is a first update to the original Guide. A writing group formulated practical answers to 15 clinical scenarios, based on available and updated knowledge. In some instances, the authors opted to make recommendations that do not fully align with all SmPC, with the goal to provide more uniform and simple practical advice. An EHRA website, www.NOACforAF.eu, accompanies the Practical Guide. Definition of “non-valvular atrial fibrillation” and eligibility for non-vitamin K antagonist oral anticoagulants Non-valvular AF refers to AF that occurs in the absence of mechanical prosthetic heart valves and in the absence of moderate to severe mitral stenosis (usually of rheumatic origin) (Table 1). Both types of patients were excluded from all NOAC trials. Mechanical prosthetic heart valves constitute a strict contraindication for the use of any NOAC until further data become available.

Název v anglickém jazyce

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Summary of the document prepared by the Czech Society of Cardiology

Popis výsledku anglicky

Introduction Non-vitamin K antagonist oral anticoagulants (NOACs) have emerged as an alternative for vitamin K antagonists (VKAs) for thrombo-embolic prevention in patients with non-valvular atrial fibrillation (AF). Some authors refer to these drugs as ‘direct oral anticoagulants’ (DOACs), but since the term NOAC has been used for many years and is widely recognized, we prefer to continue to use NOAC. Non-vitamin K antagonist oral anticoagulants have an improved efficacy/safety ratio, predictable effect without need for routine monitoring, and fewer food and drug interactions compared with VKAs. However, the proper use of NOACs requires different approaches to many practical aspects compared with VKAs. The European Heart Rhythm Association (EHRA) set out to coordinate a unified way of informing physicians on the use of NOACs. A first Practical Guide was published in 2013 to supplement the AF guidelines as a guidance for safe, effective use of NOAC when prescribed. This text is a first update to the original Guide. A writing group formulated practical answers to 15 clinical scenarios, based on available and updated knowledge. In some instances, the authors opted to make recommendations that do not fully align with all SmPC, with the goal to provide more uniform and simple practical advice. An EHRA website, www.NOACforAF.eu, accompanies the Practical Guide. Definition of “non-valvular atrial fibrillation” and eligibility for non-vitamin K antagonist oral anticoagulants Non-valvular AF refers to AF that occurs in the absence of mechanical prosthetic heart valves and in the absence of moderate to severe mitral stenosis (usually of rheumatic origin) (Table 1). Both types of patients were excluded from all NOAC trials. Mechanical prosthetic heart valves constitute a strict contraindication for the use of any NOAC until further data become available.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

COR ET VASA

ISSN

0010-8650

e-ISSN

—

Svazek periodika

60

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

PL - Polská republika

Počet stran výsledku

26

Strana od-do

"E421"-"E446"

Kód UT WoS článku

000442902500014

EID výsledku v databázi Scopus

2-s2.0-85051662246